阿立哌唑治疗老年期首发精神分裂症临床分析  

A clinical analysis of aripiprazole in the treatment of naive senile schizophrenia

作　　者：刘华莉[1] 刘玉[1] 张光勇[1] 李红[1] 

机构地区：[1]四川绵阳市精神卫生中心,621000

出　　处：《临床精神医学杂志》2008年第1期57-58,共2页Journal of Clinical Psychiatry

摘　　要：目的:比较阿立哌唑和氟哌啶醇治疗老年期首发精神分裂症的疗效和安全性。方法:将60例老年期首发精神分裂症患者随机分为阿立哌唑组和氟哌啶醇组,分别给予阿立哌唑和氟哌啶醇治疗,疗程8周。采用阳性与阴性症状量表(PANSS)评定疗效,用治疗中出现的症状量表(TESS)评定不良反应。结果:阿立哌唑与氟哌啶醇临床疗效差异无显著性,不良反应较轻。结论:阿立哌唑治疗老年期首发精神分裂症疗效好、安全性高,有利于长期巩固治疗。Objective：To compare the efficacy and safety between aripiprazole and halopefidol in the treatment of naive senile sehizophrenia Method： Sixty naive senile schizophrenia were randomly divided into aripiprazole group （aripiprazole treatment） or halopefidol group （halopefidol treatment） for 8 weeks.The positive and negative syndrome scale （PANSS） and the treatment emergent symptom scale （TESS） were used to assess the efficacy and the side effects. Results：There was no significant difference in the clinical efficacy between aripiprazole and halopefidol treatment. The patients in aripiprazole group had mild side effects. Conclusion： Aripiprazole has a good efficacy and high safety in the treatment of naive senile schizophrenia, which is favorable for long-term maintain treatment.

关 键 词：阿立哌唑 老年期 精神分裂症 氟哌啶醇 

分 类 号：R749.053[医药卫生—神经病学与精神病学]